Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
NA-Selank Amidate7 residuesTKPRPGPEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: NA-Selank, N-Acetyl Selank, Selank Amidate
Zero PubMed-indexed studies exist for NA-Selank Amidate specifically. Every efficacy claim traces back to native Selank, the Russian-approved anxiolytic heptapeptide. What the dual modification (N-acetylation plus C-amidation) adds is enzymatic stability. Native Selank vanishes from plasma in 2 to 3 minutes; the amidate form sustains functional effects for an estimated 4 to 6 hours. The parent compound matched medazepam for anxiety reduction in a 62-patient GAD trial [1]. Hundreds of reports across r/nootropics describe it as "benzodiazepine-like calm without the fog." Administered intranasally, no needles required.
NA-Selank Amidate (N-Acetyl Selank Amidate) is a stabilized derivative of Selank with anxiolytic properties that community users compare to benzodiazepines, minus the sedation, tolerance, or dependence. Hundreds of reports across r/nootropics and r/peptides describe that profile consistently. NA-Selank Amidate is built on Selank, itself a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). The N-terminal acetylation protects against aminopeptidases. The C-terminal amidation blocks carboxypeptidase degradation. Together, these modifications extend functional duration from minutes to hours after intranasal delivery. The parent compound Selank has real clinical backing. Zozulia and colleagues tested it against medazepam in 62 patients with generalized anxiety disorder over 28 days [1]. Selank matched the benzodiazepine for anxiolytic effect while adding antiasthenic and mild nootropic properties the drug comparator lacked. Separate preclinical work confirmed BDNF upregulation in the hippocampus after intranasal dosing [2] and measurable cytokine modulation under stress conditions [3]. Community protocols have adapted to the amidate form's longer half-life. Most users dose once daily at 300 to 400 mcg intranasally for 14-day courses, then take a 14 to 21 day washout. The most popular stack pairs it with NA-Semax Amidate, morning Selank for anxiolytic baseline plus morning Semax for dopaminergic focus. Formal clinical research covers native Selank only. The amidate modification uses sound mechanistic logic, but no human pharmacokinetic study has confirmed the assumed half-life extension.
NA-Selank Amidate operates through four converging pathways, all documented for the parent compound Selank in preclinical and limited clinical research. The first pathway accounts for the anxiolytic effect. Selank is a subtype-selective positive allosteric modulator of GABA-A receptors. It increases inhibitory neurotransmission without directly binding the benzodiazepine site. That distinction matters; it explains the absence of sedation, amnesia, and physical dependence that define classical benzodiazepine use. The second pathway involves endogenous opioid regulation. Selank inhibits enkephalin-degrading enzymes (enkephalinases) in blood plasma with an IC50 of approximately 15 micromolar [4]. Blocking enkephalin breakdown raises endogenous enkephalin levels, contributing to mood stabilization and mild analgesia. Third, intranasal Selank administration upregulates BDNF mRNA and protein expression in the hippocampus. Inozemtseva and colleagues confirmed this in vivo [2]. BDNF-driven synaptic plasticity underpins the memory consolidation and neuroprotective effects that emerge by the second week of daily dosing. Fourth, Selank-derived peptides modulate over 30 inflammation-related genes in immune tissue. Yasenyavskaya's group tracked reduced IL-6, IL-1-beta, and TNF-alpha alongside restored anti-inflammatory IL-4 under social stress conditions [3]. This dual neuro-immune mechanism is the basis for Selank's stress-protective properties. The N-acetyl and C-amide modifications on NA-Selank Amidate do not change these mechanisms. They slow enzymatic degradation, extending the window during which the peptide remains active after each dose.
No direct clinical or preclinical studies exist for NA-Selank Amidate as a distinct compound. Efficacy and safety data are entirely extrapolated from native Selank. The dual N-acetylation + C-amidation modification is supported mechanistically (protects against aminopeptidase and carboxypeptidase degradation) but has not been validated in human pharmacokinetic or clinical trials.
Zozulia et al. 2008 (PMID 18454096): native Selank vs. medazepam in generalized anxiety disorder (n=62, 28-day trial); Selank showed comparable anxiolytic efficacy with additional antiasthenic effects. Not specific to NA-Selank Amidate.
Zero PubMed-indexed studies for NA-Selank Amidate specifically. phase-3 designation in database applies to native Selank (Russian MoH approval 2009), not this compound. Half-life extension (~4-6 hrs estimated) is mechanistically supported but unmeasured in humans. Most recent primary Selank research: PMID 32621722 (2021 cytokines/stress model); no new 2022-2026 primary studies found.
Well-regarded anxiolytic in the nootropics community. Consistently described as "benzodiazepine-like calm without the fog." Widely stacked with NA-Semax Amidate. Community has pragmatically adopted the extended half-life by dosing once daily vs. native Selank's 3x/day.
Community protocols (once-daily dosing, 14-day cycles) are better calibrated to the extended half-life of the amidate form than the current database entry (2-3x/day, 4-week cycles). Scientific literature covers native Selank only; community application to the amidate modification uses reasonable mechanistic extrapolation but lacks direct validation.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 400mcg | Daily |
| Aggressive | 600mcg | Daily |
Most NA-Selank Amidate comes as a pre-mixed nasal spray, so reconstitution typically isn't needed. If you're working with lyophilized powder (10 mg vial), add 10 mL bacteriostatic water for a 1 mg/mL concentration. Each unit on a U100 insulin syringe then delivers 10 mcg. So 200 mcg is 20 units, 300 mcg is 30 units, 500 mcg is 50 units. The per-nostril versus total-dose labeling trap catches more beginners than any other issue. A standard 300 mcg/pump spray, one pump per nostril, delivers 600 mcg total. That's an aggressive dose on day one. Start with one pump total per session, not per nostril. Refrigerate the spray the moment you open it. "It stopped working" is the single most common troubleshooting complaint in the community; the cause is almost always room-temperature storage. Opened sprays degrade fast and should be used within 30 days. If you notice the anxiolytic effect weakening before day 14, don't increase the dose. End the course early and extend your washout to 3 weeks. The amidate form's longer receptor occupancy may speed up GABA-A desensitization compared to native Selank.
Russian clinical protocols for Selank use 14-day treatment courses intranasally 3 times daily. Many practitioners extend this to 4-week cycles with 2-week washout periods. The anxiolytic effect has been reported to persist for approximately one week after the last dose. No tolerance or dependence has been observed with repeated cycles. Some users employ continuous low-dose use (200 mcg 1-2x daily) without cycling.
NA-Selank Amidate's estimated ~4-6 hr half-life produces sustained GABA-A receptor occupancy vs. native Selank's ~2-3 min plasma half-life. Prolonged receptor occupancy is theorized to accelerate GABAergic desensitization. Russian clinical protocols for native Selank already use 14-day treatment courses: community consensus applies the same 14-day limit to the amidate form, treating the longer half-life as a reason to use shorter cycles, not longer. The database entry's 4-week cycle (onWeeks: 4) is calibrated for native Selank, not the amidate modification.
Or use the universal Peptide Calculator for any peptide.
Expected: Consistent anxiolytic effect by day 3-5; mild sleep quality improvements; effects may persist 5-7 days after last dose
Monitor: Note any paradoxical anxiety or unusual mood changes and discontinue if present. Monitor for sedation if co-using any GABAergic medication.
Blow your nose gently; you want clear airways for absorption.
Point away from your face and pump 2 to 3 times until you see a fine mist.
Insert the spray tip into one nostril. Depress the pump once while inhaling gently through your nose.
A standard spray delivers approximately 300 mcg per pump. One pump is your full dose.
For the intermediate protocol: one pump per session for 3 to 4 days, then increase to 300 to 500 mcg once daily if well tolerated.
If using twice daily on high-demand days, keep doses at least 5 hours apart and avoid dosing after 3 PM to prevent sleep interference.
Do not blow your nose for 10 to 15 minutes after application.
If using reconstituted lyophilized powder with an intranasal atomizer device (MAD) instead of pre-mixed spray: 10 mg vial plus 10 mL BAC water gives 1 mg/mL. Draw 20 units for 200 mcg, 30 units for 300 mcg, 50 units for 500 mcg. Administer via MAD attached to a 1 mL syringe.
Peak effects at 1 to 2 hours.
Discard after 30 days.
Standard reference dose; 200-500 mcg per session
Verify mcg per pump from spray concentration before first use. Standard pre-mixed sprays: 300 mcg/pump at 1.5 mg/mL is common. Refrigerate immediately after opening.
250-500 mcg per injection, once daily; total daily dose comparable to intranasal route
No head-to-head bioavailability comparison between routes for Selank family peptides. Subcutaneous allows more precise volume control than pump sprays. Reconstitute 10mg vial with 10mL BAC water for 1 mg/mL (200 mcg = 20 units U100). Intranasal atomizer device (MAD) can also be used with reconstituted solution.
Unknown: no comparative data; inconsistent community reports
Not a validated or commonly recommended route for Selank family peptides.
Most cited pairing in the Russian-derived nootropic community. Complementary mechanisms: Selank handles anxiety/GABA/immunomodulation; Semax handles dopamine/BDNF/focus. Non-overlapping effects; no known negative interaction.
Both intranasal, morning; Selank for anxiolytic baseline, Semax for cognitive performance layer
Same synergistic rationale as NA-Semax Amidate; preferred by users wanting unmodified forms or lower cost point.
Added in advanced cognitive stacks for synapse formation (HGF/Met pathway) alongside BDNF upregulation from Selank; different mechanisms, no known interaction.
Neurotrophic factor blend occasionally combined with Selank family peptides for combined neuroprotective and cognitive support protocols.
Selank potentiates diazepam effects in preclinical models; combination risks over-sedation and additive CNS depression. Mechanistically contraindicated.
Do not combineNo clinical interaction data. Selank modulates serotonin metabolism and GABA in animal models: overlapping mechanisms with antidepressants. Community consensus: cautious; warrants physician guidance before combining.
Additive CNS depressant effects via shared GABA-A modulation. Alcohol also counteracts nootropic and neuroprotective benefits.
Selank produces transient blood pressure reduction in animal studies; potential additive hypotensive effect if on antihypertensive medication.
Pricing updated 2026-04-09
No direct human safety data exists for NA-Selank Amidate as a distinct compound. Every safety profile detail below comes from native Selank studies or community reports of the amidate form. That evidence gap matters, because the extended half-life could change the side effect profile in ways that haven't been formally measured. The most clinically relevant concern is serotonergic overlap. Selank modulates serotonin metabolism and GABA activity in animal models. Anyone on SSRIs, SNRIs, or other serotonergic medications faces a theoretical interaction with no clinical data to quantify the risk. Increased sedation and serotonin-adjacent symptoms are the signals to watch for. Talk to your prescriber before combining. Benzodiazepine potentiation is documented preclinically. Selank amplifies diazepam's effects in animal models. Combining the amidate form with any benzodiazepine (diazepam, alprazolam, lorazepam) risks excessive sedation and additive CNS depression. This is a hard contraindication at anything above minimum doses. Paradoxical anxiety affects a minority of users, typically at doses above 500 mcg or after prolonged use without cycling. This reflects GABA-A receptor desensitization rather than a serotonergic mechanism. Reduce to 200 mcg; discontinue if it persists at that dose. Transient blood pressure reduction is observed in animal studies, lasting 1 to 3 minutes post-dose. Clinically, this matters only if you're on antihypertensives or prone to orthostatic hypotension. Check blood pressure with your first few doses. Mild nasal irritation or brief burning at the application site is the most common complaint. Occasional fatigue or drowsiness occurs in sensitive users. Transient headache in the first 1 to 3 days is reported by some; community users find Alpha-GPC (300 mg) mitigates this. Native Selank clinical trials (up to 28 days of daily dosing) reported no dependence, withdrawal, amnesia, or sedation. No toxicity emerged in studies running one month of continuous administration. Contraindications: pregnancy or breastfeeding (no safety data), known hypersensitivity to Selank, tuftsin, or formulation components, severe hypotension, active nasal infections or recent nasal surgery, children under 18, and autoimmune conditions where immunomodulatory effects could alter immune balance. When to stop and contact a physician: paradoxical anxiety that persists at reduced doses, excessive sedation (especially if using other GABAergic substances), signs of serotonin-like effects (agitation, tremor, hyperthermia) if on antidepressants, or symptomatic hypotension.
Verify NA-Selank Amidate dosing and safety with a second opinion
No standardized testing or regulatory framework for this compound in Western markets. Pre-mixed nasal sprays are harder to independently verify for concentration accuracy than injectable vials. Mislabeling risk: product may be native Selank rather than the amidate modification (indistinguishable without HPLC/MS). Research peptide market has variable manufacturing quality and no GMP requirement for research-labeled products.
| Test | When | Target |
|---|---|---|
| Blood pressure | First 1-3 doses; ongoing if on antihypertensives | No specific numeric target: monitor for symptomatic hypotension (lightheadedness, dizziness within 5-15 min of dose) |
| Subjective anxiety and mood log | Daily throughout 14-day course | — |
Transient hypotensive effect observed in animal studies; clinically relevant if taking antihypertensives or prone to orthostatic hypotension
Early detection of tolerance (diminishing anxiolytic effect) and rare paradoxical anxiety response; guides whether to continue or end course and extend washout
Rapid onset of mild anxiolytic effects within 20-40 minutes of intranasal administration. Subtle sense of calm and reduced mental tension. Some users report improved mental clarity and verbal fluency within the first hour. Effects peak at 1-2 hours post-dose.
Anxiolytic effects become more consistent with regular dosing. Reduced reactivity to daily stressors. Mild improvements in focus and attention. Sleep quality may improve as baseline anxiety decreases.
Nootropic effects emerge: improved memory recall, faster information processing, and better sustained attention. BDNF upregulation is underway. Mood stabilization and reduced irritability become more noticeable.
Full anxiolytic and nootropic benefits develop. Significant reduction in generalized anxiety comparable to low-dose benzodiazepines. Enhanced learning capacity and memory consolidation. Immunomodulatory effects (reduced inflammatory cytokines) contribute to improved overall well-being and stress resilience.
Anxiolytic effects persist for approximately 5-7 days after the last dose. Cognitive improvements driven by BDNF-mediated neuroplasticity may persist longer. No withdrawal symptoms, rebound anxiety, or dependence reported. Cycle can be repeated after a 2-week break.
First dose (20 to 60 minutes): You'll notice a mild but clear anxiolytic shift within 20 to 40 minutes of intranasal dosing. Think quieted mental chatter rather than sedation. Verbal fluency and mental clarity pick up for some users within the first hour. Effects peak at 1 to 2 hours. Mild nasal irritation is possible; brief lightheadedness from transient blood pressure reduction is rare and resolves within minutes. Days 1 to 5: The calming baseline becomes more reliable with daily dosing. Stressors that triggered disproportionate reactions feel more manageable. Sleep often improves as anxious arousal drops. Some users get a transient headache in days 1 to 3; Alpha-GPC (300 mg) tends to resolve it. Days 6 to 14: This is the window where nootropic effects layer on top of the anxiolytic base. Memory recall sharpens, information processing speeds up, and sustained attention improves. These changes reflect BDNF upregulation in the hippocampus reaching functional levels. Mood stabilization and reduced irritability become distinct from the acute anti-anxiety effect. Most community users call this the peak benefit window of a 14-day course. After cycling off: Direct GABA-A modulation clears within hours. The anxiolytic and mood benefits persist for roughly 5 to 7 days after your last dose. Cognitive improvements driven by BDNF-mediated neuroplasticity may last 1 to 2 weeks beyond that. No withdrawal symptoms, rebound anxiety, or dependence signs. Repeat the cycle after a minimum 14-day break.
Rapid GABA-A positive allosteric modulation following intranasal absorption (plasma detectable within 15-30 min per native Selank PK data). Enkephalinase inhibition begins within minutes of systemic exposure.
Mild but noticeable calm within 20-40 min; reduced mental tension and quieting of anxious thought patterns. Some users report improved verbal fluency and mental clarity within the first hour. Effects peak at 1-2 hrs.
Cumulative GABA-A modulation and sustained enkephalin elevation building. BDNF mRNA upregulation initiating in hippocampus (animal data: detectable within first days of daily intranasal dosing).
More consistent baseline calm; reduced reactivity to daily stressors; mild sleep quality improvements as anxious arousal decreases. Transient headache in days 1-3 for some users.
BDNF-mediated synaptic plasticity and memory consolidation developing; cytokine modulation (reduced IL-6, IL-1beta, TNF-alpha; restored IL-4) measurable in preclinical stress models by days 7-14.
Improved memory recall, faster information processing, better sustained attention. Mood stabilization and reduced irritability. Many users report this as the peak benefit window of the 14-day course.
Direct GABA-A modulation dissipates within hours as peptide clears. BDNF-driven neuroplasticity changes (synaptic strengthening) are more durable and persist beyond peptide clearance.
Anxiolytic and mood benefits reported to persist 5-7 days post-last-dose. Cognitive improvements (memory, clarity) sometimes reported for 1-2 weeks. No withdrawal, rebound anxiety, or dependence reported.
Source: Plasma t½ ~2-3 minutes for native Selank. NA-Selank Amidate has improved enzymatic stability due to N-acetylation and C-amidation, likely extending effective t½ somewhat. Functional anxiolytic and nootropic effects persist 6-8 hours due to downstream gene expression changes (BDNF upregulation, cytokine modulation) and enkephalinase inhibition.
Loading the interactive decay curve.
NA-Selank Amidate is classified as a research peptide in the United States and most Western markets. It holds no FDA approval, IND application, or regulatory pathway status in the US. The parent compound Selank received approval from the Russian Ministry of Health in 2009 as an anxiolytic for generalized anxiety disorder and neurasthenia. That approval covers the native Selank formulation, not the N-acetyl amidate modification specifically. NA-Selank Amidate is not scheduled under the Controlled Substances Act. It can be legally purchased for research purposes from peptide vendors in the US. Products are typically labeled "for research use only, not for human consumption." WADA status: Selank family peptides are not currently listed on the WADA Prohibited List, though athletes should verify current status before use, as peptide classifications are updated periodically. This content is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any research peptide.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
